Pharmacological treatment profiles in the FACE-BD cohort: Treatment description and complete data for bipolar subtypes.
Data in Brief. 2021-06-01; 36: 107004
DOI: 10.1016/j.dib.2021.107004
Lire sur PubMed
1. Data Brief. 2021 Mar 25;36:107004. doi: 10.1016/j.dib.2021.107004. eCollection
2021 Jun.
Pharmacological treatment profiles in the FACE-BD cohort: Treatment description
and complete data for bipolar subtypes.
Brodeur S(1), Terrisse H(2), Pouchon A(1), Godin O(3), Aouizerate B(4), Aubin
V(5), Bellivier F(6), Belzeaux R(7), Bougerol T(1), Courtet P(8), Dubertret
C(9), Gard S(4), Haffen E(10), Henry C(11), Leboyer M(3), Olié E(8), Roux P(12),
Samalin L(13), Schwan R(14); FondaMental Advanced Centers of Expertise in
Bipolar Disorders (FACE-BD) Collaborators; Etain B(6), Bosson JL(2), Polosan
M(1).
Author information:
(1)Service Universitaire de Psychiatrie, CHU de Grenoble et des Alpes, T.
Bougerol, B. Fredembach, A. Suisse, S. Brodeur, A. Pouchon, and M. Polosan,
Grenoble, France.
(2)TIMC-IMAG, University Grenoble Alpes, France.
(3)AP-HP, DHU PePSY, Pôle de Psychiatrie et d’Addictologie des Hôpitaux
Universitaires H Mondor, Créteil, S. Hotier, A. Pelletier, N. Drancourt, JP.
Sanchez, E. Saliou, C. Hebbache, J. Petrucci, L. Willaume and E. Bourdin,
France.
(4)Hôpital C. Perrens, Centre Expert Trouble Bipolaire, Service de Psychiatrie
Adulte, Pôle 3-4-7, B. Antoniol, A. Desage, S. Gard, A. Jutant, K. Mbailara, I.
Minois, and L. Zanouy, Bordeaux, France.
(5)Centre Hospitalier Princesse Grace, V. Aubin, I. Cussac, M.A Dupont, J.
Loftus, and I. Medecin, Monaco, France.
(6)AP-HP, GH Saint-Louis-Lariboisière-Fernand Widal, Pôle Neurosciences, F.
Bellivier, M. Carminati, B. Etain, E. Marlinge, M. Meyrel, Paris, France.
(7)Pôle de Psychiatrie, addictologie et pédopsychiatrie, Hôpital Sainte
Marguerite, R. Belzeaux, N. Correard, F. Groppi, A. Lefrere, L. Lescalier., E.
Moreau, J. Pastol, M. Rebattu, B. Roux and N. Viglianese, Marseille, France.
(8)Département d’Urgence et Post Urgence Psychiatrique, CHRU Montpellier, C.
Abettan, L. Bardin, A. Cazals, P. Courtet, B. Deffinis, D. Ducasse, M. Gachet,
A. Henrion, E. Martinerie, F. Molière, B. Noisette, E. Olié and G. Tarquini,
Montpellier, France.
(9)AHPH, Departement de Psychiatrie, Hopital Louis Mourier, C. Dubertret, N.
Mazer, C. Portalier, Colombes, France.
(10)Service de psychiatrie, CHU de Besançon, Laboratoire de Neurosciences,
Université de Franche-Comté, E. Haffen, France.
(11)Université Paris Descartes, Pôle Hospitalo-Universitaire Paris 15ème, GHU,
Centre Hospitalier Sainte Anne, France.
(12)Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie
d’adultes, A. M. Galliot, I. Grévin, A. S. Cannavo, N. Kayser, C. Passerieux,
and P. Roux; Service de Psychiatrie, Le Chesnay, France.
(13)CHU de Clermont Ferrand, Pôle de Psychiatrie, Clermont Ferrand: Service de
Psychiatrie de l’adulte B, Centre Expert Trouble Bipolaire, CHU de
Clermont-Ferrand, PM. Llorca, L. Samalin, L., C. Moreau, D. Lacelle, S.Pires, C.
Doriat, and O. Blanc, Clermont-Ferrand, France.
(14)Service de Psychiatrie et Psychologie Clinique, CHU de Nancy, Hôpitaux de
Brabois, R. Cohen, Raymond Schwan, J. P. Kahn, M. Milazzo, and O.
Wajsbrot-Elgrabli, Vandœuvre Les Nancy, France.
In the current study, we provide the list of pharmacological interventions
applied during the one-year follow-up period of the Pharmacological treatment
profiles in the FACE-BD cohort study. These data show the treatments used in the
new clusters formed in this previous study and also in usual bipolarity
subtypes. The proportion of each treatment used during the follow-up was
calculated. Days on each treatment were also included in this dataset. The
complete clinical and paraclinical data analyzed for clusters and bipolar
subtypes were included in this dataset. Socio-demographic self-administered and
clinician-administered scales, clinical evaluation during the follow-up,
psychiatric and somatic comorbidities, and blood tests are shown in this
material.
© 2021 The Authors.
DOI: 10.1016/j.dib.2021.107004
PMCID: PMC8027517
PMID: 33855141
Conflict of interest statement: Dr. Brodeur, H. Terrisse, Dr. Pouchon, O. Godin,
Dr. Aubin, Dr. Bellivier, Dr. Belzeaux, Dr. Bougerol, Dr. Courtet, Dr.
Dubertret, Dr. Gard, Dr. Henry, Dr. Leboyer, Dr. Roux, Dr. Schwan, Dr. Bosson
have nothing to disclose. Dr. Aouizerate reports personal fees from
Janssen-Cilag, personal fees from Lilly, personal fees from Sanofi, during the
conduct of the study. Dr. Haffen reports personal fees and non-financial support
from Janssen, personal fees and non-financial support from Lundbeck, personal
fees and non-financial support from Otsuka, outside the submitted work. Dr. Olié
reports personal fees from Janssen-Cilag, outside the submitted work. Dr.
Samalin reports personal fees and non-financial support from Janssen, personal
fees and non-financial support from Lundbeck, personal fees and non-financial
support from Otsuka, outside the submitted work. Dr. Etain reports grants from
INSERM, grants from Assistance Publique des Hôpitaux de Paris, grants from
Agence Nationale pour la Recherche, grants from Fondation de France, grants from
Research Council of Norway, personal fees from SANOFI, outside the submitted
work. Dr. Polosan reports personal fees from Lundbeck, personal fees from
Janssen-Cilag, outside the submitted work. The FondaMental Advanced Centers of
Expertise in Bipolar Disorders (FACE-BD) Collaborators have no conflicts of
interest to disclose except PM Llorca. PM Llorca has received grants, honoraria,
or consulting fees from ESAI, Gedeon Richeter, Janssen, Lundbeck, Otsuka and
Sanofi.